Mattel(MAT)
Search documents
Mattel Sales Declines Slow as Toys Make a Cautious Comeback
PYMNTS.com· 2024-07-23 22:44
After years of consumers cutting back on nonessential retail purchases, Mattel is now starting to feel optimistic about the future of toys sales. On Tuesday (July 23), the toy and entertainment giant, owner of iconic brands including Barbie, Hot Wheels, Fisher-Price, American Girl and many others, reported its second quarter 2024 financial results. On a call with analysts, Ynon Kreiz, the company’s chairman and CEO, related improvements in the toys sector. “The toy industry performed better than anticipated ...
Mattel(MAT) - 2024 Q2 - Earnings Call Presentation
2024-07-23 22:41
Second Quarter 2024 Earnings (Unaudited Results) July 23, 2024 Cautionary Note Regarding Forward-Looking Statements / Presentation Information Mattel cautions the viewer that this presentation contains a number of forward-looking statements, which are statements that relate to the future and are, by their nature, uncertain. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include statements regarding Mattel's guidance and goals for ...
Mattel (MAT) Tops Q2 Earnings Estimates
ZACKS· 2024-07-23 22:26
Mattel (MAT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.75%. A quarter ago, it was expected that this toy maker would post a loss of $0.12 per share when it actually produced a loss of $0.05, delivering a surprise of 58.33%.Over the last four quarters, the company has surpasse ...
Mattel(MAT) - 2024 Q2 - Quarterly Results
2024-07-23 20:06
NEWS RELEASE Exhibit 99.1 MATTEL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Second Quarter 2024 Highlights Versus Prior Year • Net Sales of $1,080 million, down 1% as reported, and comparable in constant currency • Gross Margin of 49.2%, an increase of 410 basis points; Adjusted Gross Margin of 49.2%, an increase of 430 basis points • Operating Income of $83 million, an improvement of $20 million; Adjusted Operating Income of $96 million, an improvement of $21 million • Net Income of $57 million, an impr ...
Buyout Barbie? Mattel Stock Jumps on Reports of Takeover Interest.
Investor Place· 2024-07-22 18:16
Toy manufacturer and entertainment specialist Mattel (NASDAQ:MAT) generated business headlines earlier today on reports of a takeover interest. According to Reuters, private equity firm L Catterton — which is backed by luxury goods brand LVMH (OTCMKTS:LVMUY) — offered to buy out the toy company. Mattel stock likely jumped as prior efforts to turn the ship around have not succeeded.Per the report, the news of the asset management firm’s interest in acquiring the entertainment specialist may prompt competing ...
Toy maker Mattel receives buyout offer from L Catterton, sending shares soaring 20%
New York Post· 2024-07-22 17:12
L Catterton, the private equity firm backed by luxury goods giant LVMH, has approached Mattel, the toy maker behind Barbie and Hot Wheels, with an acquisition offer, people familiar with the matter said Monday.The move could prompt other potential suitors to consider bids for Mattel, including rival Hasbro, which has become aware of L Catterton’s approach and is discussing whether it should also submit an offer, one of the sources said. Hasbro and Mattel have held unsuccessful merger talks over the years.Th ...
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
Prnewswire· 2024-07-08 10:00
~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE39 ...
Mattel's UNO and other popular games will become colorblind accessible
CNBC· 2024-06-25 16:25
Mattel aims to make 80% of its games colorblind accessible by the end of the year, before raising that amount to 90% in 2025, the company announced Tuesday.Mattel said the move is part of an inclusivity effort and will target some of its most popular products, including Uno, Phase 10, Dos, Blokus and Tumblin' Monkeys games, according to a press release. The toy manufacturer's portfolio-wide changes will ensure that classic colors are not the only way to differentiate cards or components for the majority of ...
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
GlobeNewswire News Room· 2024-06-24 12:30
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at N ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
Prnewswire· 2024-06-24 10:00
Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024, including RECIST 1.1 clinical efficacy waterfall, swim-lane plot, ctDNA molecular response analysis, AE profile, PK and pharmacodynamicsInitiating IDE397 Phase 2 monotherapy expansion in MTAP bladder cancer, in addition to the earlier reported Phase 2 expansion in MTAP squamous lung cancerActivated over 35 clinical trial sites globally across the U.S., Canada, Euro ...